Inici › Càncer de pulmó › Illinois › Joliet
Assaigs clínics de Càncer de pulmó a Joliet, IL
12 estudis de Càncer de pulmó busquen participants en centres de Joliet i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutantFase 3
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · a 6 mi
- University of Chicago Medicine-Orland Park, Orland Park · a 14 mi
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
ReclutantFase 3
- Northwestern Medicine Orland Park, Orland Park · a 14 mi
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ReclutantFase 3
- Northwestern Medicine Orland Park, Orland Park · a 14 mi
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
ReclutantFase 2
- Hope and Healing Clinical Research, New Lenox · a 6 mi
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ReclutantFase 3
- Hope and Healing Cancer Services, New Lenox · a 6 mi
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
ReclutantFase 2
- Hope and Healing Clinical Research, New Lenox · a 6 mi
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
ReclutantFase 3
- Hope and Healing Cancer Services, New Lenox · a 6 mi
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
ReclutantFase 1/2
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · a 6 mi
- University of Chicago Medicine-Orland Park, Orland Park · a 14 mi
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
ReclutantFase 1
- University of Chicago, New Lenox · a 6 mi
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ReclutantFase 2
- Northwestern Medicine Orland Park, Orland Park · a 14 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2
- Northwestern Medicine Orland Park, Orland Park · a 14 mi
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2/3
- Northwestern Medicine Orland Park, Orland Park · a 14 mi
Assaigs de Càncer de pulmó en altres ciutats
- Houston, TX78 estudis
- Boston, MA62 estudis
- New York City, NY60 estudis
- Los Angeles, CA45 estudis
- Washington, DC41 estudis
- Arlington, VA41 estudis
- Chicago, IL41 estudis
- Nashville, TN40 estudis
- Baltimore, MD40 estudis
- St. Louis, MO39 estudis
- Columbus, OH37 estudis
- Philadelphia, PA36 estudis
Altres estudis a Joliet
- Càncer de pulmó de cèl·lules no petites12 estudis
- Càncer metastàtic7 estudis
- Càncer de bufeta7 estudis
- Carcinoma de cèl·lules escamoses de cap i coll6 estudis
- Càncer de pròstata5 estudis
- Càncer hipofaringi5 estudis
- Càncer de laringe5 estudis
- Càncer oral5 estudis
- Leucèmia mieloide aguda5 estudis
- Càncer de mama4 estudis
- Càncer de còlon4 estudis
- Càncer de ronyó (carcinoma de cèl·lules renals)4 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.